S&P 500
(0.11%) 5 254.35 points
Dow J
(0.12%) 39 807 points
Nasdaq
(-0.12%) 16 379 points
Oil
(2.16%) $83.11
Gas
(1.98%) $1.752
Gold
(1.90%) $2 254.80
Silver
(1.41%) $25.10
Platinum
(1.45%) $922.85
USD/EUR
(0.36%) $0.927
USD/NOK
(0.73%) $10.85
USD/GBP
(0.13%) $0.792
USD/RUB
(0.15%) $92.58

Realtime updates for Blueprint Medicines Corp [BPMC]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
78.57%
return 18.07%
SELL
44.44%
return 0.32%
Last Updated28 Mar 2024 @ 16:00

0.07% $ 94.86

SELL 1798 min ago

@ $91.30

Issued: 27 Mar 2024 @ 11:56


Return: 3.90%


Previous signal: Mar 26 - 11:38


Previous signal: Buy


Return: 2.47 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 0.81% compare to its pairs and should correct upwards.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally...

Stats
Today's Volume 602 986
Average Volume 814 908
Market Cap 5.81B
EPS $0 ( 2024-02-15 )
Next earnings date ( $-1.650 ) 2024-05-02
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -11.33
ATR14 $2.23 (2.35%)
Insider Trading
Date Person Action Amount type
2024-03-07 Albers Jeffrey W. Sell 11 033 Common Stock
2024-03-20 Albers Jeffrey W. Buy 10 000 Common Stock
2024-03-20 Albers Jeffrey W. Sell 2 730 Common Stock
2024-03-20 Albers Jeffrey W. Sell 6 251 Common Stock
2024-03-20 Albers Jeffrey W. Buy 15 073 Common Stock
INSIDER POWER
37.01
Last 100 transactions
Buy: 592 922 | Sell: 279 297
Correlation (AI algo v.1.1b): Undervalued: 0.81% $95.63 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: 0.43 (neutral)
Short: 0.05 (neutral)
Signal:(57) Neutral

Blueprint Medicines Corp Correlation

10 Most Positive Correlations
ACBA0.958
MANH0.953
PUCK0.951
VIRI0.949
GXII0.947
AEAC0.946
ESLT0.946
RAM0.946
IVCB0.945
SKYW0.945
10 Most Negative Correlations
PEAR-0.951
VORB-0.949
INFN-0.934
MKTX-0.931
BHTG-0.928
FEMY-0.927
IVAC-0.926
EDUC-0.926
TRIT-0.925
OBNK-0.924

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Blueprint Medicines Corp Correlation - Currency/Commodity

The country flag 0.13
( neutral )
The country flag -0.19
( neutral )
The country flag 0.00
( neutral )
The country flag -0.08
( neutral )
The country flag -0.22
( neutral )
The country flag -0.16
( neutral )

Blueprint Medicines Corp Financials

Annual 2023
Revenue: $249.38M
Gross Profit: $224.92M (90.19 %)
EPS: $-8.37
Q4 2023
Revenue: $71.96M
Gross Profit: $70.17M (97.51 %)
EPS: $-1.820
Q3 2023
Revenue: $56.57M
Gross Profit: $52.01M (91.95 %)
EPS: $-2.20
Q2 2023
Revenue: $57.57M
Gross Profit: $55.25M (95.96 %)
EPS: $-2.19

Financial Reports:

No articles found.

Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators